Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat

• Published in: Leukemia & lymphoma 2018-01, Vol.59 (1), p.69-76
• Main Authors: Gautam, Ashish, Zhu, Yanyan, Ma, Esprit, Lee, Shih-Yuan, Zagadailov, Erin, Teasell, Jeremy, Richhariya, Akshara, Bonthapally, Vijayveer, Huebner, Dirk
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological - therapeutic use; Brentuximab vedotin; CD30; Combined Modality Therapy; Consolidation Chemotherapy; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease - drug therapy; Hodgkin Disease - mortality; Hodgkin Disease - pathology; Hodgkin lymphoma; Humans; Immunoconjugates - therapeutic use; Intention to Treat Analysis; Male; Middle Aged; Neoplasm, Residual - pathology; numbers needed to treat; Proportional Hazards Models; Risk Factors; Transplantation, Autologous; Treatment Outcome; Young Adult
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2017.1324160

The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of disease progression/death was evaluated. AETHERA included 329 Hodgkin lymphoma patients at increased risk of progression post-ASCT who received brentuximab vedotin 1.8 mg/kg (n = 165) or placebo (n = 164) on day 1 of each 21-d cycle (up to 16 cycles). Over 60 months, the NNT with brentuximab vedotin ranged from 4.08 to 7.79 for the intent-to-treat population, 3.18-6.07 for patients with ≥2 risk factors, and 2.98-5.65 for patients with ≥3 risk factors. At various time points, and dependent on the risk group, 3-8 patients would need to be treated with brentuximab vedotin consolidation therapy to prevent a disease progression/death, compared with placebo. Patients with increased risk of relapse may benefit most from brentuximab vedotin.